Eli Lilly and Company
Eli Lilly and Company (United States) holds 0 active US FDA Type II Drug Master Files and 40 inactive, has DMF or CEP filings on record for 14 active ingredients and is linked to 6 FDA-registered manufacturing sites. 15 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Eli Lilly and Company: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/eli-lilly-and-company
Overview
Eli Lilly and Company is a global pharmaceutical company known for its innovative contributions to the field of medicine. The company develops, manufactures, and markets pharmaceutical products across a wide range of therapeutic areas. It is committed to advancing medical research and improving patient outcomes.
Core services & business areas
Therapeutic areas
Active ingredients with DMF or CEP filings
Substances for which Eli Lilly and Company holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Eli Lilly and Company holds 0 active (40 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- MDX-068 (HUMANIZED ANTI-B-AMYLOID MONOCLONAL ANTIBODY)Inactive2004-03-15
- DIPEPTIDYLAMINOPEPTIDASE (DDAP)Inactive2001-06-05
- CAPREOMYCIN SULFATE, STERILE BULK (CAPASAT)Inactive2001-02-27
- RECOMBINANT PORCINE CARBOXYPEPTIDASE B (RCPB)Inactive2000-09-18
- RECOMBINANT BOVINE TRYPSIN (RTRYPSIN)Inactive2000-09-18
- DIPEPTIDYLAMINOPEPTIDASE (DDAP)Inactive1998-12-08
- CEFACLORInactive1998-09-01
- CEFACLORInactive1998-09-01
- ERYTHROMYCINInactive1998-09-01
- PENICILLIN G PROCAINEInactive1998-09-01
- VANCOMYCIN HYDROCHLORIDEInactive1998-09-01
- CEFAMANDOLE SODIUMInactive1998-09-01
- CEFAMANDOLE NAFATEInactive1998-09-01
- ERYTHROMYCIN ESTOLATEInactive1998-09-01
- CEFUROXIME SODIUMInactive1998-09-01
- CEFAMANDOLE NAFATEInactive1998-09-01
- CYCLOSERINEInactive1998-09-01
- CEPHALEXIN HYDROCHLORIDE,BULKInactive1985-11-12
- BULK PRODUCTION OF NIZATIDINEInactive1985-09-23
- BULK PRODUCTION OF NIZATIDINEInactive1985-09-23
- ACETOHEXAMIDE BULK FORMInactive1984-06-20
- ACETOHEXAMIDE BULK FORMInactive1984-06-20
- CINOXACIN, BULK FORMInactive1983-11-15
- FENOPROFEN CALCIUM, BULK FORMInactive1983-09-16
- AMPOULES SODIUM THIOSULFATEInactive1980-09-30
- VIALS DANTRIUM (R)Inactive1979-09-25
- ACETAMINOPHEN CAPSULESInactive1979-08-22
- ROTOWEIGH (TM) CAPSULE WEIGHING MACHINE AT USED IN THE INDIANAPOLIS PLInactive1979-03-14
- ZINC INSULIN CRYSTALS--ARGENTINA DMF-2912Inactive1976-12-22
- NITROGLYCERIN AMPOULESInactive1972-05-01
- ASPIRIN CAPSULES 325MGInactive1971-08-02
- MANUF AND CONTROL INFOR. FOR METHADONE HYDROCHLORIDE DISPERSIBLE TBLSInactive1970-05-27
- AMPOULES SODIUM THIOCYANATE, INJECTION COMPOUND #23206Inactive1965-12-27
- TYLOSINInactive1960-06-16
- IMIDAZOLIUM BROMIDE DERIVATIVEInactive1960-05-16
- VORTEL TABLETSInactive1959-11-16
- MYRISTYL - 3 - HYDROXYBUTYLAMINE HCL - COMPOUND 06537Inactive1959-04-20
- 1 - CYCLOPPENTYL - 2 - AMINO PROPANEInactive1958-08-29
- CHLORDIETHYLNOL (DIETHYL CHLORO ETHYNYL CARBINOL)Inactive1957-04-08
- TOPICAL ANESTHETIC COMPOUND C-10Inactive1955-12-22
Registered manufacturing sites (6)
Physical sites registered with the US FDA and resolved to Eli Lilly and Company, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
- Eli Lilly and CompanyIndianapolis, United States · API manufacture
- Eli Lilly Italia SPASesto Fiorentino, Italy · Analytical testing · LabellingSite GMP match
- Eli Lilly Kinsale LimitedCo Cork, Ireland · API manufacture
- Lilly del Caribe, Inc.Carolina, United States · API manufacture
- Lilly FranceFegersheim, France · Analytical testing · Labelling
- Lilly S.A.Madrid, Spain · Analytical testing · Drug manufactureSite GMP match
FDA compliance signals
15 FDA enforcement records linked to this company.
- warning_letter2025-09-09
FDA Warning Letter (drug product)
- recall — Class II2024-04-24
CGMP Deviations
- 4832023-09-15
Failure to comply with REMS Elements to Assure Safe Use (ETASU) D
- 4832023-09-15
Failure to comply with REMS Elements to Assure Safe Use (ETASU) C
- 4832023-09-15
Failure to comply with REMS Elements to Assure Safe Use (ETASU) A
- 4832023-09-15
Failure to comply with REMS Elements to Assure Safe Use (ETASU) F
- 4832023-09-15
Failure to comply with REMS Elements to Assure Safe Use (ETASU) B
- recall — Class I2021-10-20
SUBPOTENT DRUG: Vial contained a liquid substance, instead of the expected powder substance. There was also a lack of full drug effect upon administration.
- recall — Class II2021-09-01
Labeling: Label error on declared strength - autoinjector devices labeled as 0.75 mg / 0.5 mL actually contain 1.5 mg / 0.5 mL of product.
- recall — Class II2021-08-18
cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.
- recall — Class III2018-11-21
Labeling: Missing label; potential for missing primary container label on the vial.
- 4832018-04-23
Late submission of quarterly safety reports
- 4832010-09-03
Late submission of 15-day report
- 4832010-07-28
In-process materials specifications
- 4832010-07-28
Procedures not in writing, fully followed
Is this Eli Lilly and Company?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.